Detalhe da pesquisa
1.
Switching to Interleukin-23 Inhibitors After Ineffectiveness of Ustekinumab: Evaluating Real-World Outcomes in Psoriasis Treatment.
Am J Clin Dermatol
; 25(4): 685-688, 2024 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-38802618